Drug intelligence / Profile preview

mesoglycan

Development stage
Phase 4
Lead developer
Mediolanum Farmaceutici
Administration
Oral, Intramuscular, Intravenous, Topical
01

Overview

Mesoglycan is a natural glycosaminoglycan (GAG) preparation, a sulfated polysaccharide extract typically obtained from porcine intestinal mucosa, cow lung, or cow blood vessel (aorta). It is composed primarily of heparan sulfate, dermatan sulfate, and slow-moving heparin, with smaller, variable quantities of chondroitin sulfate. Mesoglycan is utilized for its multifaceted effects on the vascular system, including antithrombotic, profibrinolytic, anti-inflammatory, antiedema, and wound-healing properties. It is approved in many European countries for the treatment of various blood vessel homeostasis diseases and is also marketed as a dietary supplement. Its therapeutic applications span conditions such as peripheral arterial disease, chronic venous disease, leg ulcers, deep vein thrombosis, and cerebrovascular diseases.

Brand names
Prisma
Other names
Aortic glycosaminoglycanGAGGlycosaminoglycanMesoglycan sodium
02

Targets

ATIII (Antithrombin III)SERPIND1 (Heparin cofactor II)SDC4 (Syndecan-4)AMPK (Adenosine monophosphate–activated protein kinase)F10 (Factor Xa)mTOR (Mammalian target of rapamycin kinase)F2 (Thrombin)PLAT (Tissue-type plasminogen activator)

Beyond the preview

Go deeper on mesoglycan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mesoglycan.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call